WeVote
Log In

Bill

Bill

HB 5442

Relating to training on the uses and indications of certain drugs for pregnant women.

2026 Regular Session Introduced by Sarah Drennan and 4 co-sponsors

Requires training for healthcare professionals on the uses and indications of certain drugs used during pregnancy.

To House Health and Human Resources
#health
0
WeVote Research Nonpartisan
Bill Summary · HB 5442

Summary of HB 5442 (Session 2026, West Virginia)

Title

Relating to training on the uses and indications of certain drugs for pregnant women.

Purpose and intent

  • To require or authorize training regarding the uses and indications of certain drugs for pregnant women.
  • The bill aims to ensure that individuals involved in care or prescribing for pregnant patients are informed about appropriate drug use during pregnancy and the drugs’ indications.

Note: The text provided is largely garbled/encoded, but the available title and context indicate a focus on professional training related to pharmacology uses/indications for drugs in pregnancy.

Key provisions (as implied by title and sponsor information)

  • Training Requirement: Establish or mandate training on the uses and indications of specific drugs when treating pregnant women. This could apply to certain health professionals (e.g., prescribers, pharmacists, obstetric care providers) or to health care facilities delivering prenatal care.
  • Scope of Drugs: The bill references “certain drugs” used during pregnancy. The exact list is not clearly visible in the provided text, but it would specify which medications are covered (e.g., commonly used obstetric drugs, antiemetics, analgesics, mood stabilizers, etc.) and their indicated uses in pregnancy.
  • Training Content: Likely components would include:
    • Evidence-based indications for the drugs during pregnancy
    • Safety considerations and contraindications
    • Risk-benefit assessment for pregnant patients
    • Monitoring and management of adverse effects
  • Training Delivery: The bill probably specifies how training should be delivered (e.g., through continuing education for clinicians, mandatory in-service training for facilities, or certification requirements).
  • Compliance and Verification: Provisions may include reporting, documentation, or verification requirements to demonstrate completion of the training.

Who would be affected

  • Healthcare professionals who treat or manage medications for pregnant patients (e.g., obstetricians, family physicians, midwives, pharmacists, nurse practitioners, physician assistants).
  • Healthcare facilities and practices providing prenatal care.
  • Potentially medical residents or students if the training is to be integrated into licensure or certification processes.

Timelines and procedural aspects

  • Status: Filed for introduction on 2026-02-11; referred to Health and Human Resources; introduced in the House and assigned to House Health and Human Resources.
  • Sponsors: Primary sponsor(s) and co-sponsors include:
    • Co-sponsors: Sarah Drennan, Kathie Hess Crouse, Erica Moore, Evan Worrell, Joe Ellington
  • Effective date and implementation timeline are not legible in the provided text. Bills of this nature typically include:
    • A phased implementation (e.g., compliance within 12–24 months after enactment)
    • Deadlines for training completion reporting
    • Possible exemptions or carve-outs (e.g., for certain types of practitioners or institutions)

Potential impact

  • Educational impact: Improves consistency and quality of care for pregnant patients through standardized training on pharmacologic uses and indications.
  • Patient safety: Aims to reduce inappropriate drug use in pregnancy and strengthen risk-benefit discussions with patients.
  • Professional practice: Could lead to mandatory continuing education credits or certification-related requirements for prescribers and pharmacists.
  • Administrative: May require tracking of training completion, record-keeping, and periodic renewals.

If you have access to the official bill text or a more legible version, I can refine this summary with exact provisions, definitions, drug lists, and precise deadlines.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.